When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Rigetti Computing shares increased 11% in Monday's premarket session in what may be a continuation of a rally in quantum computing companies following the launch Google's Willow quantum chip earlier ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Discover the first FDA-approved weight loss medication for obstructive sleep apnea, Zepbound by Eli Lilly. Learn how it can reduce apnea events and CPAP market.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...